×

Intellectual Property Patents

  • TOKYO— Nikon Corp. said Monday it has taken legal action in the Netherlands, Germany and Japan over the use of semiconductor lithography technology in products made by Dutch and German companies. Nikon said it is seeking to stop Dutch company ASML Holding N.V. and its supplier Carl Zeiss SMT GmbH from using patented technology without its permission.

  • April 18- U.S. generic drug company Argentum Pharmaceuticals LLC said on Tuesday it had reached an agreement with Allergan Plc that settles a patent dispute over the generic version of Allergan's eye drug, Restasis. The agreement gives Argentum the right to sell the copycat version of Restasis before the patents covering the drug expire, Argentum said.

  • April 17- IRobot, the maker of the popular Roomba robotic vacuum, brought a string of lawsuits on Monday accusing rivals including The Hoover Co and Black& Decker Corp of using its patented technology without permission. Bedford, Massachusetts- based iRobot filed lawsuits in federal court in Boston against Hoover, Black& Decker, Bobsweep Inc and Bissell Homecare...

  • April 13- The University of California is appealing a U.S. patent ruling over the game-changing gene editing technology known as CRISPR that favored the Broad Institute, a research affiliate of Harvard University and the Massachusetts Institute of Technology. The appeal filed in the U.S. Court of Appeals for the Federal Circuit was announced Thursday by the...

  • April 13- The University of California at Berkeley and University of Vienna in Austria have appealed a ruling allowing a research center affiliated with MIT and Harvard to keep valuable patents on a revolutionary gene-editing technology known as CRISPR. Patent and Trademark Office's Patent Trial and Appeal Board in Alexandria, Virginia, in February ruled...

  • April 13- The University of California at Berkeley and University of Vienna in Austria have appealed a ruling allowing a research center affiliated with MIT and Harvard to keep valuable patents on a revolutionary gene-editing technology known as CRISPR. Patent and Trademark Office's Patent Trial and Appeal Board in Alexandria, Virginia, in February ruled...

  • George Scangos, CEO of Biogen.

    According to a filing from the U.S. Patent and Trademark Office, Forward Pharma has been interfering with Biogen.

  • March 31- A federal judge in Delaware on Friday struck down key patents held by Acorda Therapeutics Inc related to its multiple sclerosis drug Ampyra, causing the stock to tumble 24 percent before trading was halted. District Judge Leonard Stark opens the door for generic versions of the drug by companies including Mylan Inc and Roxane Laboratories Inc..

  • March 31- A U.S. patent board on Friday ruled against Danish drugmaker Forward Pharma A/S, finding Biogen's patents on its blockbuster multiple sclerosis drug Tecfidera to be valid. Patent Trial and Appeal Board frees Bigoen Inc from future royalty payments to Forward and sent the Danish firm's shares down nearly 20 percent. The companies had been locked in a...

  • March 31- A federal judge in Delaware on Friday struck down key patents held by Acorda Therapeutics Inc related to its multiple sclerosis drug Ampyra, and the stock fell 24 percent before being halted. District Judge Leonard Stark opens the door for generic versions of the drug by makers including Mylan Inc and Roxane Laboratories Inc.. Sales of Ampyra...

  • District Judge Leonard Stark opens the door for generic versions of the drug by makers including Mylan Inc and Roxane Laboratories Inc, who had been sued by Acorda.

  • The Sam B. Hall Jr. federal courthouse in Marshall, Texas.

    Companies are buying, but not using, patents in Texas and then demanding royalties and suing for damages, NYT reports.

  • WASHINGTON, March 27- The U.S. Supreme Court on Monday struggled over whether to upend nearly 30 years of law governing patent lawsuits that critics say allows often-baseless litigants to sue in friendly courts, giving them the upper hand over high-technology companies such as Apple Inc and Alphabet Inc's Google. The justices heard an hour of arguments in an...

  • WASHINGTON, March 27- The U.S. Supreme Court on Monday struggled over whether to upend nearly 30 years of law governing patent lawsuits that critics say allows often-baseless litigants to sue in friendly courts, giving them the upper hand over high-technology companies such as Apple Inc and Alphabet Inc's Google. The justices heard an hour of arguments in an...

  • LONDON, March 27- International groups representing doctors and patients have launched a fresh challenge to the patent on Gilead Sciences' hepatitis C drug sofosbuvir at the European Patent Office in order to increase access to the treatment. If the latest patent challenge is successful, it could make cheaper generic versions of sofosbuvir available in...

  • March 21- A U.S. Supreme Court ruling on Tuesday in a lawsuit over adult diapers will make it more difficult for companies accused of patent infringement to shoot down lawsuits because the plaintiffs waited too long to bring them. In a 7-1 decision, the justices said SCA Hygiene Products AB, based in Stockholm, did not unreasonably delay in filing a lawsuit...

  • Biogen wins patent decision

    CNBC's Meg Tirrell reports on the victory for Biogen in its patent case over its Multiple Sclerosis drug.

  • Last month, the Broad Institute, a biological and genomic research center affiliated with MIT and Harvard, won a landmark ruling to keep valuable patents on CRISPR. Cambridge, Massachusetts- based Editas Medicine licenses CRISPR-related intellectual property from the Broad Institute. Editas had cash and cash equivalents of $185.3 million as of Dec. 31.

  • Pilot models of the Uber self-driving car is displayed at the Uber Advanced Technologies Center on September 13, 2016 in Pittsburgh, Pennsylvania.

    Alphabet's self-driving car unit Waymo added a new patent claim to its intellectual property lawsuit against Uber Technologies.

  • March 13- Data that should help unlock the sales potential of a potent new cholesterol medicine will be unveiled at the American College of Cardiology meeting this week as the future of the only rival drug rests with the courts in an ongoing patent dispute. Highly anticipated results from a 27,500- patient trial of Amgen Inc's Repatha will be presented on...